Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
During its most recent quarterly earnings, Johnson & Johnson announced plans to separate its Orthopedics business to enhance strategic and operational focus. The transaction would establish a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback